Article Information
History
- June 13, 2022.
Article Versions
- You are currently viewing Version 1 of this article (June 13, 2022 - 22:24).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Heli Julkunen1,
- Anna Cichońska1,
- Mika Tiainen1,
- Harri Koskela1,
- Kristian Nybo1,
- Valtteri Mäkelä1,
- Jussi Nokso-Koivisto1,
- Kati Kristiansson2,
- Markus Perola2,
- Veikko Salomaa2,
- Pekka Jousilahti2,
- Annamari Lundqvist2,
- Antti J. Kangas1,
- Pasi Soininen1,
- Jeffrey C. Barrett1 and
- Peter Würtz1,*
- 1Nightingale Health Plc, Helsinki, Finland
- 2Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland
- ↵*Address for Correspondence:
Peter Würtz, Nightingale Health, Mannerheimintie 164a, 00300 Helsinki, Finland. Peter.wurtz{at}nightingalehealth.com
Posted June 13, 2022.
Atlas of plasma nuclear magnetic resonance biomarkers for health and disease in 118,461 individuals from the UK Biobank
